Literature DB >> 15954836

Limitations of fluoroscopic intraoperative cholangiography in cases suggestive of choledocholithiasis.

John Griniatsos1, Evangelos Karvounis, Alberto M Isla.   

Abstract

BACKGROUND: Fluoroscopic intraoperative cholangiography (IOC) has been proposed as a safe and accurate screening method for choledocholithiasis, with a sensitivity and specificity of nearly 100% in selected cases. In the present study we retrospectively reviewed the diagnostic accuracy of IOC in cases highly suggestive of choledocholithiasis.
MATERIALS AND METHODS: Between January 1999 and December 2002, 103 patients underwent IOC as an imaging method for common bile duct (CBD) stone detection. We did not routinely perform IOC in all patients who were submitted to laparoscopic cholecystectomy, reserving the method for patients with a high probability of choledocholithiasis, namely patients with a history or the presence of painful obstructive jaundice at the time of referral, patients with a history of mild acute pancreatitis of biliary origin, and patients with abnormalities in their liver biochemistry profile as measured by liver function tests (LFT).
RESULTS: The mean rates of sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for IOC were 98%, 94%, 94.5%, and 98% for the whole series, respectively. The diagnostic accuracy was 100% in patients with a history of obstructive jaundice or liver biochemical derangement, but was less in patients with a history of biliary pancreatitis. There were 3 false positive cases and 1 case of false negative results, all of which occurred in the subgroup of patients with a history of pancreatitis.
CONCLUSION: Selective fluoroscopic IOC is generally feasible and safe, as well as highly accurate (100%) for CBD stone detection in patients with obstructive jaundice or abnormal LFT. The PPV of the method decreases in patients with a history of pancreatitis (75%), while a negative result is highly suggestive of the absence of CBD stones (NPV = 98%). The present study concluded in a higher incidence of false results in patients with a normal size CBD, suggesting that the diagnostic accuracy of IOC is probably related to the size of the CBD rather than the indication for its performance.

Entities:  

Mesh:

Year:  2005        PMID: 15954836     DOI: 10.1089/lap.2005.15.312

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  6 in total

1.  Comparison between intraoperative cholangiography and choledochoscopy for ductal clearance in laparoscopic CBD exploration: a prospective randomized study.

Authors:  Anubhav Vindal; Jagdish Chander; Pawanindra Lal; Balu Mahendra
Journal:  Surg Endosc       Date:  2014-08-26       Impact factor: 4.584

Review 2.  [Common bile duct stones. Diagnostic and therapeutic management].

Authors:  S Förster; E Klar
Journal:  Chirurg       Date:  2008-09       Impact factor: 0.955

Review 3.  Choledocholithiasis: evolving standards for diagnosis and management.

Authors:  Marilee-L Freitas; Robert-L Bell; Andrew-J Duffy
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

4.  Endoscopic Stone Extraction followed by Laparoscopic Cholecystectomy in Tandem for Concomitant Cholelithiasis and Choledocholithiasis: A Prospective Study.

Authors:  Doraiswami Babu Vinish; Gautham Krishnamurthy; Patta Radhakrishna; Arulprakash Sarangapani; Senthil Ganesan; Jayapriya Ramas; Ragavendran Kalyanasundaram; Balakrishnan S Ramakrishna
Journal:  J Clin Exp Hepatol       Date:  2021-03-19

5.  Role of magnetic resonance cholangiography in the diagnosis of bile duct lithiasis.

Authors:  Damir Miletic; Miljenko Uravic; Marzena Mazur-Brbac; Davor Stimac; Davor Petranovic; Branko Sestan
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.282

6.  Various techniques for the surgical treatment of common bile duct stones: a meta review.

Authors:  Abolfazl Shojaiefard; Majid Esmaeilzadeh; Ali Ghafouri; Arianeb Mehrabi
Journal:  Gastroenterol Res Pract       Date:  2009-08-06       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.